Editas Medicine (EDIT) CFO logs small automatic tax-related stock sale

Rhea-AI Filing Summary

Editas Medicine, Inc. Senior Vice President and Chief Financial Officer Amy Parison reported an open-market sale of 474 shares of common stock at a weighted average price of $2.02 per share on March 3, 2026. According to the disclosure, the sale was executed under a durable automatic sales instruction plan adopted on July 7, 2022 and was made solely to cover tax withholding obligations arising from restricted stock units that vested on March 2, 2026, rather than as a discretionary trade. After this transaction, Parison directly owned 15,434 shares of Editas Medicine common stock.

Insights

Equity compensation and insider-trading specialist

Small, pre-planned tax sale by EDIT CFO, routine and non-discretionary.

The filing shows Editas Medicine CFO Amy Parison sold 474 shares of common stock at about $2.02 per share. The footnote states this resulted from a durable automatic sales plan adopted on July 7, 2022 to satisfy tax withholding on vested restricted stock units.

Because the sale was tied to tax obligations from RSU vesting on March 2, 2026, it is characterized as non-discretionary rather than an active decision to reduce exposure. After the sale, Parison directly held 15,434 shares, indicating the transaction was small relative to her remaining stake.

For investors, this type of automatic tax-related sale is a common feature of equity compensation programs and typically does not signal a change in management’s outlook. The disclosure also notes the trade was executed in multiple lots between $2.0050 and $2.0204, with the reported price reflecting a weighted average.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Parison Amy

(Last) (First) (Middle)

11 HURLEY STREET

(Street)

CAMBRIDGE MA 02141

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Editas Medicine, Inc. [ EDIT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		S(1)		474	D	$2.02(2)	15,434	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 7, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on March 2, 2026. The sale does not represent a discretionary trade by the Reporting Person.

2. This transaction was executed in multiple trades at prices ranging from $2.0050 to $2.0204. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

	/s/ Amy Parison	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Editas Medicine (EDIT) CFO Amy Parison report in this Form 4 filing?

Editas Medicine CFO Amy Parison reported selling 474 shares of common stock. The sale occurred on March 3, 2026 at a weighted average price of about $2.02 per share and was disclosed as part of routine insider transaction reporting.

Was the Editas Medicine (EDIT) CFO’s sale a discretionary trade?

The sale was not a discretionary trade by the CFO. It was executed under a durable automatic sales instruction plan adopted July 7, 2022, specifically to meet tax withholding obligations from restricted stock units that vested on March 2, 2026.

How many Editas Medicine (EDIT) shares did the CFO sell and at what price?

The CFO sold 474 shares of Editas Medicine common stock. The transaction was executed in multiple trades between $2.0050 and $2.0204 per share, with a reported weighted average sale price of $2.02 per share in the Form 4.

Why were Editas Medicine (EDIT) shares sold in this insider transaction?

Shares were sold to satisfy tax withholding obligations tied to vested restricted stock units. The Form 4 states the sale was necessary to cover taxes from RSUs that vested on March 2, 2026 and was carried out under a pre-established automatic plan.

How many Editas Medicine (EDIT) shares does the CFO hold after this Form 4 sale?

After the reported sale, the CFO directly owned 15,434 shares of Editas Medicine common stock. This indicates the 474-share transaction represented a relatively small portion of her overall direct holdings following the tax-related sale.

What trading range is disclosed for the Editas Medicine (EDIT) CFO’s Form 4 sale?

The transaction was executed in multiple trades within a narrow price range. According to the footnote, individual trades occurred between $2.0050 and $2.0204 per share, with the Form 4 reporting a weighted average sale price of $2.02.